Estudio en fase I, abierto y multicéntrico, de HMPL-306 en neoplasias malignas hematológicas avanzadas con mutaciones de la isocitrato deshidrogenasa (IDH)

Dades bàsiques

Protocol:: 2020-306-GLOB1
EURDRACT:: 2020-003751-15
NCT:
Centre:: HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:: 2021
Any de finalització:: 2024

ENSAYO CLÍNICO

Objectius del projecte

Objetivo Principal: Parte 1: Evaluar la seguridad y tolerabilidad de HMPL-306 en sujetos con neoplasias malignas hematológicas avanzadas que albergan mutaciones de la IDH Parte 2: Caracterizar la seguridad y la tolerabilidad de HMPL-306, así como determinar su DRF2 en sujetos con neoplasias malignas hematológicas avanzadas que albergan mutaciones de la IDH Objetivos Secundarios: - Evaluar la actividad antitumoral preliminar de HMPL-306 en sujetos con neoplasias malignas hematológicas avanzadas que albergan mutaciones de la IDH - Evaluar la farmacocinética (FC) de HMPL-306 en sujetos con neoplasias malignas hematológicas avanzadas que albergan mutaciones de la IDH - Evaluar la farmacodinámica (FD) de HMPL-306 en sujetos con neoplasias malignas hematológicas avanzadas que albergan mutaciones de la IDH

Documents

No hi ha documents

Participants

Shirley Weiss

Data Manager / Study Coordinator
Francisco Buendía Fuentes

Investigador Colaborador
David Pellicer Bossis

Data Manager / Study Coordinator
Irene Torres Espallardo

Investigador Colaborador
David Martínez Cuadrón

Investigador Colaborador
Rebeca Rodríguez Veiga

Investigador Colaborador
Consuelo Olivas Arroyo

Investigador Colaborador
María Rodríguez Serrano

Investigador Colaborador
Ana María Osa Sáez

Investigador Colaborador
José Luis Poveda Andrés

Investigador Colaborador
Blanca Boluda Pascual

Investigador Colaborador
Isabel Cano Ferri

Investigador Colaborador
Maria Perez Fernandez

Técnico Apoyo Investigación
Eva Barragán González

Investigador Colaborador
Pau Montesinos Fernández

Investigador Principal
Elisa González Romero

Data Manager / Study Coordinator
Álvaro Fernández Pardo

Data Manager / Study Coordinator
Marta Eusebio Garagalza

Data Manager / Study Coordinator
Evelyn Gloria Acuña Cruz

Investigador Colaborador
Anselmo Feliciano Sanchez

Investigador Colaborador
Romana Garcia Gil

Investigador Colaborador
Ana Maria Yepes Agudelo

Investigador Colaborador
Sonia Gines Cardenas

Investigador Colaborador
Africa Almendros Riaza

Investigador Colaborador
Laura Torres Miñana

Investigador Colaborador
Fatima Tomas Medina

Investigador Colaborador
Oussama Bardouz Gouguasse

Investigador Colaborador
Silvia Maestro Huguet

Investigador Colaborador
Maria Del Mar San Juan Tubilleja

Investigador Colaborador
Ainoa Del Carmen Vizuete Bolaños

Data Manager / Study Coordinator
María Del Pilar Lloret Madrid

Investigador Colaborador
Nuria Capdepon Tortosa

Data Manager / Study Coordinator
Natalia Pallardó Navarro

Data Manager / Study Coordinator

Veure tots els Investigadors

Grups d'Investigació

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos
Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí
Farmacogenética

Investigador Principal

María José Herrero Cervera
Investigacion Biomédica en Imagen (GIBI 2-30)

Investigador Principal

Leonor Cerdá Alberich
Núcleo de investigación traslacional integrado Urológico de Valencia (NITIUV)

Leader

César David Vera Donoso
Unidad de Descubrimiento de Fármacos (UDF)

Investigador Principal

Leonor Puchades Carrasco
Grupo de Investigación de Farmacia

Investigador Principal

Javier García Pellicer

Finançadors - Promotors

Hutchison MediPharma Limited

Resultats de l'Assaig Clínic

Publicacions en Revistes 278

[[en]]Peripheral access ultrafiltration in adults with complex congenital heart disease and refractory congestion.

Guerrero Cervera B; (...); Almenar Bonet L

Article. 10.1016/j.rec.2024.08.015. 2024

[[Tranaslated article]]Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.

López DF; (...); Ortiz-Romero, P. L.

Article. 10.1016/j.ad.2022.11.013. 2023

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025

[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Zabaleta, Aintzane; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-184797. 2023

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Perez Miguez, Carlos; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2024-201407. 2024

A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.

Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose

Article. 10.3390/ijms25042112. 2024

A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Bergua Burgues, Juan Miguel; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189676. 2023

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022

A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Burgues, Juan Miguel Bergua; (...); Curran, Emily K.

Meeting Abstract. 10.1182/blood-2024-208792. 2024

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

Daver, Naval Guastad; (...); Sallman, David Andrew

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS6585. 2024

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)

Daver, Naval Guastad; (...); Sweet, Kendra Lynn

Meeting Abstract. 2023

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146585. 2021

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.

Rodríguez-Arbolí E; (...); Montesinos P

Article. 10.1002/cncr.35618. 2024

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.

Montesinos, Pau; (...); McMullin, Mary Frances

Article. 10.1007/s00280-023-04516-9. 2023

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

Zeidner JF; (...); Douglas Smith B

Letter. 10.1038/s41408-021-00568-3. 2021

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy

Jamy, Omer Hassan; (...); Cicic, Dragan

Meeting Abstract. 2023

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

Berard, Emilie; (...); Recher, Christian

Article. 10.1038/s41408-022-00700-x. 2022

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146681. 2021

A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?

Solana-Altabella A; (...); Montesinos P

Article. 10.1007/s00277-024-05891-w. 2024

Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

Erba, Harry; (...); Fathi, Amir

Meeting Abstract. 2023

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.

Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group

Article. 10.1016/j.leukres.2022.106821. 2022

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Montesinos, Pau; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2021-147805. 2021

Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1016/j.ejmp.2024.103345. 2024

AN INTERIM ANALYSIS OF FOVOCIP: A MULTICENTER RANDOMIZED TRIAL OF FOSFOMYCIN VERSUS CIPROFLOXACIN FOR FEBRILE NEUTROPENIA PREVENTION IN HEMATOLOGIC PATIENTS

Fernandez Moreno, Ahinoa; (...); Bernal, Teresa

Meeting Abstract. 2024

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.

Fiedler, Walter; (...); Blum, William

Article. 10.3324/haematol.2022.281128. 2022

Antireconverin antibodies in ocular chronic graft versus host disease: A new cause of nonparaneoplasic autoimmune retinopathy

Aguilar Gonzalez, Marina; (...); Espana Gregori, Enrique

Article. 10.1177/11206721221123779. 2022

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Venditti, Adriano; (...); Pullarkat, Vinod A.

Meeting Abstract. 10.1182/blood-2022-158500. 2022

Artificial Intelligence on FDG PET Images Identifies Mild Cognitive Impairment Patients with Neurodegenerative Disease.

Prats-Climent, Joan; (...); Marti-Bonmati, Luis

Article. 10.1007/s10916-022-01836-w. 2022

Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023

Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights.

Gil, Jose Vicente; (...); Llop, Marta

Article. 10.3390/ijms26010357. 2025

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.

Wei, AH; (...); DiNardo, CD

Article. 10.1038/s41408-021-00565-6. 2021

Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.

Sánchez R; (...); Martínez-López J

Correction. 10.1038/s41598-024-57570-5. 2024

Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.

Serrano, Josefina; (...); Montesinos, Pau

Article. 10.1016/j.jtct.2025.02.011. 2025

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Labrador J; (...); Montesinos P

Article. 10.3390/cancers14092342. 2022

Biallelic TET2 mutation sensitizes to 5'-azacitidine in acute myeloid leukemia.

Stölzel F; (...); Allan, James M.

Article. 10.1172/jci.insight.150368. 2022

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2022-160127. 2022

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2022-158030. 2022

CA125: a new biomarker in patients with Fontan circulation (vol 76, pg 112, 2023)

Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda

Correction. 10.1016/j.rec.2023.03.018. 2023

CA125: a new biomarker in patients with Fontan circulation.

Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda

Article. 10.1016/j.rec.2022.05.029. 2022

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood-2023-177571. 2023

Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Romero, Alejandra; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-163869. 2022

Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients

Espallardo, I. Torres; (...); Prado-Wohlwend, S.

Meeting Abstract. 2023

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Vicente, Navarro; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-190296. 2023

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Bernal, Teresa; (...); Montesinos, Pau

Article. 10.1002/cam4.6120. 2023

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl, Alexander E.; (...); Altman, Jessica K.

Article. 10.1038/s41408-022-00677-7. 2022

Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Colmenares, Rafael; (...); Montesinos, Pau

Meeting Abstract. 2023

ComBat harmonization in different PET imaging scenarios

Gandia-Ferrero, M.; (...); Marti-Bonmati, L.

Meeting Abstract. 2023

Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.

Martinez-Movilla, Andrea; (...); Carles, Montserrat

Article. 10.1186/s40658-022-00509-4. 2022

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Sargas, Claudia; (...); Montesinos, Pau

Article. 10.1038/s41408-023-00835-5. 2023

Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3389/fmolb.2024.1362081. 2024

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil C; (...); Genesca E

Article. 10.3324/haematol.2024.285416. 2024

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Boluda, Blanca; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-160136. 2022

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)

Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez

Correction. 10.3389/fonc.2023.1302993. 2023

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Lancet, Jeffrey; (...); Carraway, Hetty E.

Meeting Abstract. 10.1182/blood-2023-173149. 2023

COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Rosenberg, Aaron; (...); Khouri, Jack

Meeting Abstract. 2023

Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study

Pfeilstoecker, M.; (...); Roboz, G. J.

Meeting Abstract. 2022

Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Article. 10.3390/cancers15113039. 2023

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.

Schuh, Andre C.; (...); Montesinos, Pau

Meeting Abstract. 2022

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group

Article. 10.3390/cancers14112817. 2022

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Gonzalez, Carmen; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-180646. 2023

Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.

Montesinos, Pau, Sossa-Melo, Claudia

Article. 10.1016/S2352-3026(23)00308-3. 2023

Decreased clinical performance in TGA-ASO patients after RVOT interventions; a multicenter European collaboration.

Engele LJ; (...); Bouma BJ

Article. 10.1016/j.ijcard.2024.132027. 2024

Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model

Poyatos-Garcia, Javier; (...); Vilchez, Juan J

Article. 10.1186/s13395-024-00353-3. 2024

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.

Montesinos P; (...); DiNardo CD

Article. 10.1182/bloodadvances.2023011914. 2024

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Suárez EU; (...); Montesinos P

Article. 10.1007/s00277-024-05840-7. 2024

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Hutchings, Martin; (...); Subklewe, Marion

Meeting Abstract. 10.1182/blood-2023-173302. 2023

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Montesinos, Pau; (...); Recher, Christian

Meeting Abstract. 10.1182/blood-2024-194356. 2024

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo

Article. 10.3389/fonc.2022.968340. 2022

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan

Meeting Abstract. 10.1182/blood-2022-163016. 2022

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Labrador, Jorge; (...); Montesinos, Pau

Article. 10.1002/cncr.35431. 2024

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180710. 2023

Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia

Sossa, Claudia; (...); Marcela Cuervo, Diana

Meeting Abstract. 2023

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM; (...); Sancho JM

Article. 10.3324/haematol.2023.283342. 2024

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).

Jabbour, Elias; (...); Ribera, Josep-Maria

Meeting Abstract. 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Jabbour, Elias; (...); Ribera, Jose-Maria

Meeting Abstract. 2023

FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety

Moreno, Ainhoa Fernandez; (...); Bernal, Teresa

Article. 10.1186/s13063-023-07702-5. 2023

Free automatic software for quality assurance of computed tomography calibration, edges and radiomics metrics reproducibility.

Saborido-Moral, Juan D.; (...); Carles, Montserrat

Article. 10.1016/j.ejmp.2023.103153. 2023

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil, Celia; (...); Genesca, Eulalia

Article. 10.3324/haematol.2022.281196. 2023

GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS

Santiago, M.; (...); Cervera-Zamora, J.

Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Sekeres MA; (...); Cortes JE

Article. 10.1038/s41375-023-02001-z. 2023

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.

Salamero, Olga; (...); Montesinos, Pau

Article. 10.1016/S2352-3026(24)00132-7. 2024

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Pinero, Paula; (...); Tarin, Fabian

Article. 10.3390/cancers14164010. 2022

Identifying prognostic gene panels in acute myeloid leukemia.

Sanchez-Garcia, Joaquin; (...); Montesinos, Pau

Article. 10.1080/17474086.2023.2193322. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 10.1182/blood-2022-169011. 2022

IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P; (...); Ribera JM

Article. 10.1097/HS9.0000000000000810. 2023

IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS

de la Fuente, Adolfo; (...); Tormo, Mar

Meeting Abstract. 2023

Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.

Ayala, Rosa; (...); Montesinos, Pau

Article. 10.3390/cancers14235799. 2022

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.

Kayser, Sabine; (...); Schlenk, Richard F.

Article. 10.3324/haematol.2022.282127. 2023

Impact on Survival of Heart and Heart-Lung Transplantation in Patients With Cyanotic and Noncyanotic Congenital Heart Diseases.

Donoso-Trenado, Victor; (...); Almenar-bonet, Luis

Article. 10.1016/j.transproceed.2024.12.005. 2024

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Marconi, Giovanni; (...); Martinelli, Giovanni

Meeting Abstract. 10.1182/blood-2023-184745. 2023

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Sobas, Marta; (...); Montesinos, Pau

Article. 10.1007/s00277-023-05582-y. 2023

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024

In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Labrador, Jorge; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-162591. 2022

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.

Simoes C; (...); Paiva B

Article. 10.1182/bloodadvances.2022008141. 2023

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Papayannidis, Cristina; (...); Vyas, Paresh

Meeting Abstract. 10.1182/blood-2022-156296. 2022

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study

de Botton, Stephane; (...); Doehner, Hartmut

Meeting Abstract. 2023

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Montesinos, Pau; (...); Dombret, Herve

Meeting Abstract. 10.1182/blood-2023-187286. 2023

ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-168945. 2022

Left atrial strain in adults after the arterial switch operation for transposition of the great arteries.

Buendia-Fuentes, Francisco; (...); Rueda, Joaquin

Article. 10.1111/echo.15750. 2024

LONG TERM OUTCOMES OF ADULTS WITH SINGLE VENTRICLE PHYSIOLOGY NOT UNDERGOING FONTAN REPAIR: A MULTICENTRE EXPERIENCE.

Buendia-Fuentes, Francisco; (...); Rueda-Soriano, Joaquin

Article. 10.1016/j.cjca.2021.06.001. 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei, Andrew H.; (...); Roboz, Gail J.

Letter. 10.1002/ajh.26847. 2023

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner, Joshua F; (...); Vyas, Paresh

Article. 10.1182/blood.2024027408. 2025

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Alfonso Pierola, Ana; (...); Prosper, Felipe

Meeting Abstract. 10.1182/blood-2023-188865. 2023

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study

Doehner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-159473. 2022

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Sargas, Claudia; (...); On Behalf Of Pethema Group

Article. 10.3390/cancers15020438. 2023

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin, Chenyu; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.01.031. 2023

Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-185760. 2023

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Objective Image Quality Comparison Between Brain-Dedicated PET and PET/CT Scanners.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1007/s10916-023-01984-7. 2023

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stephane; (...); Cortes, Jorge

Article. 10.1182/bloodadvances.2022009411. 2023

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Cortes, Jorge E.; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-167330. 2022

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M.; (...); Cortes, Jorge E.

Article. 10.1016/S2352-3026(22)00292-7. 2022

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp

Article. 10.1186/s13045-024-01657-z. 2025

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

Cortes J; (...); Watts JM

Article. 10.1080/10428194.2024.2333451. 2024

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Article. 10.3324/haematol.2022.282506. 2024

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Venditti, Adriano; (...); Pullarkat, Vinod

Meeting Abstract. 10.1182/blood-2023-182045. 2023

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Ashaye, Ajibade; (...); Guo, Shien

Meeting Abstract. 2024

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.

Wang, Eunice S.; (...); Tiu, V, Ramon

Article. 10.1182/blood.2021014586. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Daver NG; (...); Kantarjian HM

Article. 10.1016/S1470-2045(23)00674-5. 2024

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2023-173413. 2023

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1002/hem3.67. 2024

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Aldoss, Ibrahim; (...); Jabbour, Elias

Meeting Abstract. 10.1182/blood-2023-179537. 2023

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Jabbour, Elias; (...); Ribera, Jose-Maria

Article. 10.1001/jama.2024.4783. 2024

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2022-166937. 2022

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.

Falkenhain-Lopez, D; (...); Ortiz-Romero, P L

Article. 10.1016/j.ad.2022.11.010. 2023

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Dohner, Hartmut; (...); Lopes de Menezes D

Article. 10.1182/blood.2022016293. 2022

Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Uriel Suarez, Edwin; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-167365. 2022

QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)

Levis, Mark J.; (...); Perl, Alexander E.

Meeting Abstract. 2023

Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Levis, Mark J.; (...); Perl, Alexander

Meeting Abstract. 10.1182/blood-2022-162739. 2022

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)

Perl, Alexander; (...); Levis, Mark J.

Meeting Abstract. 10.1182/blood-2023-186785. 2023

QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2024

QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Erba, Harry P.; (...); Montesinos, Pau

Meeting Abstract. 2024

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba, Harry P.; (...); Schlenk, Richard F.

Article. 10.1016/S0140-6736(23)00464-6. 2023

Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML

Schlenk, R.; (...); Erba, H.

Meeting Abstract. 2022

Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases.

Olivan-Sasot, P; (...); Olivas-Arroyo, C

Article. 10.1016/j.rxeng.2021.03.001. 2023

Real-world experience with CPX-351 in high-risk acute myeloid leukemia.

Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti

Article. 10.1016/j.critrevonc.2023.103984. 2023

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Requena, Gaspar Aspas; (...); Matinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-190128. 2023

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.

Montesinos, Pau; (...); Heuser, Michael

Article. 10.3390/cancers16101824. 2024

Relationship between neuroimaging and emotion recognition in Mild Cognitive Impairment patients.

Gandia-Ferrero, Maria Teresa; (...); Marti-Bonmati, Luis

Article. 10.1016/j.bbr.2023.114844. 2024

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.

Torrent, Anna; (...); Ribera, Josep-Maria

Article. 10.1111/ejh.14031. 2023

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Vives, Susana; (...); PETHEMA Grp

Article. 10.3390/cancers16234028. 2024

Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Espinoza, Marcela; (...); Martinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-185288. 2023

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2023

Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry

Tura, G. Teixido; (...); Cabrera, F.

Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Torrent, Anna; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2024-207954. 2024

Sleep Duration and Cutaneous Melanoma Aggressiveness. A Prospective Observational Study in 443 Patients.

Gómez Olivas JD; (...); Martinez-García MA

Case Reports. 10.1016/j.arbr.2020.10.017. 2021

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueno, Alberto; (...); Hasan, Maroof

Article. 10.1016/j.leukres.2024.107497. 2024

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

Pinana, JL; (...); Bosch F

Article. 10.1080/10428194.2021.1992619. 2021

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Shallis RM; (...); Zeidan AM

Article. 10.1016/S2352-3026(23)00159-X. 2023

State of the art and future perspectives of new radionuclides in Nuclear Medicine.

Rosales, J J; (...); Quincoces, G

Article. 10.1016/j.remnie.2025.500082. 2025

Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)

Pfeilstoecker, M.; (...); Doehner, H.

Meeting Abstract. 2023

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Ravandi, Farhad; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2022-159045. 2022

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Pfeilstoecker, Michael; (...); Menezes, Daniel

Meeting Abstract. 2022

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Ravandi, Farhad; (...); Roboz, Gail J

Article. 10.1111/bjh.19202. 2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH; (...); Ravandi F

Article. 10.3324/haematol.2022.282296. 2023

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E; (...); Zabaleta A

Article. 10.1182/bloodadvances.2024013212. 2024

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180482. 2023

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.

Villar, Sara; (...); Montesinos, Pau

Article. 10.3389/fonc.2022.1054458. 2022

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189800. 2023

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Lloret-Madrid, Pilar; (...); Montesinos, Pau

Article. 10.1002/cncr.35696. 2025

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Erba, Harry P.; (...); Wang, Eunice S.

Meeting Abstract. 10.1182/blood-2022-167412. 2022

Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2023

Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine

Heuser, M.; (...); Doehner, H.

Meeting Abstract. 2023

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.

Saiz-Rodriguez, M; (...); Montesinos, P

Article. 10.3390/cancers13225677. 2021

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

Labrador J; (...); Montesinos P

Article. 10.3390/cancers14071734. 2022

VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS

Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora

Meeting Abstract. 2021

Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.

De la Torre EP; (...); Montesinos P

Letter. 10.3324/haematol.2023.284601. 2024

VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Pratz, Keith W.; (...); Fiedler, Walter

Article. 10.1038/s41408-022-00668-8. 2022

WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients

Ortiz Lopez, Alicia; (...); de la Fuente Burguera, Adolfo

Meeting Abstract. 2023

Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.

Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene

Article. 10.1007/s13246-024-01452-7. 2024

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Wang ES; (...); Fathi AT

Article. 10.1016/S1470-2045(24)00386-3. 2024